Eli Lilly Free Cash Flow 2010-2024 | LLY
Eli Lilly annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Eli Lilly free cash flow for the quarter ending March 31, 2024 was 179.70, a year-over-year.
- Eli Lilly free cash flow for the twelve months ending March 31, 2024 was , a year-over-year.
- Eli Lilly annual free cash flow for 2023 was $0.793B, a 86.17% decline from 2022.
- Eli Lilly annual free cash flow for 2022 was $5.731B, a 5.36% decline from 2021.
- Eli Lilly annual free cash flow for 2021 was $6.056B, a 18.48% increase from 2020.
| Eli Lilly Annual Free Cash Flow |
| 2023 |
792.50 |
| 2022 |
5,731.40 |
| 2021 |
6,056.10 |
| 2020 |
5,111.70 |
| 2019 |
3,802.70 |
| 2018 |
4,313.90 |
| 2017 |
4,538.80 |
| 2016 |
3,887.40 |
| 2015 |
1,991.00 |
| 2014 |
3,311.10 |
| 2013 |
4,902.30 |
| 2012 |
4,421.40 |
| 2011 |
6,587.80 |
| 2010 |
6,187.10 |
| 2009 |
3,588.20 |
| Eli Lilly Quarterly Free Cash Flow |
| 2024-03-31 |
179.70 |
| 2023-12-31 |
792.50 |
| 2023-09-30 |
2,175.00 |
| 2023-06-30 |
955.80 |
| 2023-03-31 |
1,062.10 |
| 2022-12-31 |
5,731.40 |
| 2022-09-30 |
4,569.40 |
| 2022-06-30 |
2,969.90 |
| 2022-03-31 |
2,157.60 |
| 2021-12-31 |
6,056.10 |
| 2021-09-30 |
4,085.80 |
| 2021-06-30 |
2,791.30 |
| 2021-03-31 |
1,397.10 |
| 2020-12-31 |
5,111.70 |
| 2020-09-30 |
3,751.20 |
| 2020-06-30 |
2,337.70 |
| 2020-03-31 |
124.10 |
| 2019-12-31 |
3,802.70 |
| 2019-09-30 |
2,165.50 |
| 2019-06-30 |
918.80 |
| 2019-03-31 |
107.60 |
| 2018-12-31 |
4,313.90 |
| 2018-09-30 |
3,259.50 |
| 2018-06-30 |
1,407.50 |
| 2018-03-31 |
200.00 |
| 2017-12-31 |
4,538.80 |
| 2017-09-30 |
3,238.80 |
| 2017-06-30 |
1,600.40 |
| 2017-03-31 |
170.90 |
| 2016-12-31 |
3,887.40 |
| 2016-09-30 |
2,217.30 |
| 2016-06-30 |
783.10 |
| 2016-03-31 |
-373.40 |
| 2015-12-31 |
1,991.00 |
| 2015-09-30 |
1,282.50 |
| 2015-06-30 |
451.30 |
| 2015-03-31 |
-273.40 |
| 2014-12-31 |
3,311.10 |
| 2014-09-30 |
2,263.70 |
| 2014-06-30 |
869.30 |
| 2014-03-31 |
70.30 |
| 2013-12-31 |
4,902.30 |
| 2013-09-30 |
3,460.10 |
| 2013-06-30 |
1,722.30 |
| 2013-03-31 |
221.50 |
| 2012-12-31 |
4,421.40 |
| 2012-09-30 |
3,210.60 |
| 2012-06-30 |
1,848.30 |
| 2012-03-31 |
721.80 |
| 2011-12-31 |
6,587.80 |
| 2011-09-30 |
4,873.70 |
| 2011-06-30 |
2,976.00 |
| 2011-03-31 |
1,074.70 |
| 2010-12-31 |
6,187.10 |
| 2010-09-30 |
4,185.30 |
| 2010-06-30 |
2,590.30 |
| 2010-03-31 |
832.90 |
| 2009-12-31 |
3,588.20 |
| 2009-09-30 |
1,808.70 |
| 2009-06-30 |
677.30 |
| 2009-03-31 |
-69.10 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$731.812B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
